Newsroom

Urban League, CSL Behring Partner to Address Community Needs including Public Health, Workforce Diversity, Leadership Development

KING OF PRUSSIA, Pa. and PHILADELPHIA, Pa. - 6 Urban League Affiliates across U.S. to participate -- starting with Philade…

CSL Behring To Present New Real-World Data on Outcomes Following Acute Coronary Syndrome at American Heart Association Scientific Sessions 2020

KING OF PRUSSIA, Pa. Global biotherapeutics leader reinforces commitment to cardiovascular research: Hosts Learning Studio…

CSL Behring Publishes Design for First-Ever Outcomes Study of ApoA-I to Reduce Risk of Cardiovascular Events in Heart Attack Patients

KING OF PRUSSIA, Pa. The AEGIS-II trial is evaluating the efficacy and safety of CSL112 (apolipoprotein A-1 [human]) duri…

Orphan Drug Designation Granted for CSL Behring’s Investigational Plasma-Derived Hemopexin Therapy for Sickle Cell Disease

KING OF PRUSSIA, Pa. • Both US and European regulators grant special designation • Phase 1 clinical development underw…

CSL Named as One of the World’s Best Employers

KING OF PRUSSIA, Pa. - Forbes Recognizes Global Biotechnology Leader for Fourth Straight Year

CSL’s Broad Response to COVID-19 and Advancements Across the Company’s Strategic Scientific Platforms are the Focus of Annual R&D Day

MELBOURNE, AU and KING OF PRUSSIA, PA • Vaccine, hyperimmune and monoclonal antibodies all in clinical stages as potential…

First Patient Enrolled in NIH Phase 3 Trial to Evaluate Potential COVID-19 Hyperimmune Medicine

Osaka, JAPAN and King of Prussia, Pa., USA • The Alliance’s anti-COVID-19 Hyperimmune Globulin (CoVIg-19) medicine is und…

U.S. Food and Drug Administration Approves HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) for Prevention of Hereditary Angioedema (HAE) Attacks in Pediatric Patients

KING OF PRUSSIA, PA HAEGARDA is the first and only subcutaneous prophylactic HAE treatment approved for children 6 years of …